1-pyridin-2-yl-1,2-dihydro-3H-pyrazol-3-one | 126583-32-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-pyridin-2-yl-1,2-dihydro-3H-pyrazol-3-one
• 英文别名: 1-(pyridin-2-yl)-1H-pyrazol-3(2H)-one；3-Hydroxy-1-(2-pyridyl)-1H-pyrazole；2-pyridin-2-yl-1H-pyrazol-5-one
• CAS: 126583-32-2
• 化学式: C₈H₇N₃O
• 分子量: 161.163
• InChiKey: UAPKLGLVGBGMRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-pyridin-2-yl-1,2-dihydro-3H-pyrazol-3-one 在 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 为溶剂， 反应 16.0h， 生成 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile
  参考文献：
  名称：

  Discovery of Novel Heteroarylazoles That Are Metabotropic Glutamate Subtype 5 Receptor Antagonists with Anxiolytic Activity

  摘要：

  The highly potent, selective, and brain-penetrant metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (47) and 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (48) are reported. Compound 47 is active in the rat fear-potentiated startle (FPS) model of anxiety with ED50 = 5.4 mg/kg (po) when dosed acutely. In this model the anxiolytic effects of 47 rapidly tolerate on repeated dosing.

  DOI：

  10.1021/jm049828c
• 作为产物：
  描述：

  2-(3-ethoxy-1H-pyrazol-1-yl)pyridine 在 三溴化硼 、 水 作用下， 以 二氯甲烷 、 乙醇 为溶剂， 反应 48.0h， 以84%的产率得到1-pyridin-2-yl-1,2-dihydro-3H-pyrazol-3-one
  参考文献：
  名称：

  N-arylation of 3-alkoxypyrazoles, the case of the pyridines

  摘要：

  In the course of a research program focused on the preparation of libraries of new chemical entities derived from 3-alkoxypyrazoles, we studied their N-pyridylation using 2, 3 or 4-bromopyridines This was achieved using Cristau and Taillefer copper-catalyzed arylation method and mostly led to the 3-alkoxy-1H-pyrazol-1-yl pyridine isomer along with lesser amount of the alternative 5-alkoxy-1H-pyrazol-1-yl pyridine The structures of these isomers were often established via their chemical tansformations and sometimes recourse to unambiguous synthetic routes for comparison purposes The alternative use of 2-fluoropyridine-based arylation was also investigated and lifted some of the limitations encountered in the course of this study (C) 2010 Elsevier Ltd All rights reserved

  DOI：

  10.1016/j.tet.2010.02.032

文献信息

• SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE
  申请人：Jeske Mario

  公开号：US20090269420A1

  公开（公告）日：2009-10-29

  The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

  本申请涉及新颖的取代二氢吡唑酮衍生物，其制备方法，它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物，特别是心血管和血液疾病、肾脏疾病以及促进伤口愈合的用途。
• SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES
  申请人：Thede Kai

  公开号：US20100305085A1

  公开（公告）日：2010-12-02

  The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.

  这项发明涉及式(I)的二氢吡唑酮衍生物，以及它们的生产方法，它们用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物，特别是心血管和血液疾病、肾脏疾病以及促进伤口愈合的用途。
• SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS
  申请人：Thede Kai

  公开号：US20120264704A1

  公开（公告）日：2012-10-18

  The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

  本申请涉及新颖的取代二氢吡唑酮衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物，特别是心血管和血液病以及肾脏疾病，并促进伤口愈合。
• SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF
  申请人：Thede Kai

  公开号：US20100093803A1

  公开（公告）日：2010-04-15

  The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

  本申请涉及新型取代二吡啶基二氢吡唑酮衍生物，其制备过程，其用于治疗和/或预防疾病以及其用于制备治疗和/或预防疾病的药物，特别是心血管和血液学疾病、肾脏疾病以及促进伤口愈合的药物。
• Preparation of 1-(het) aryl-3-hydroxypyrazoles
  申请人：BASF Aktiengesellschaft

  公开号：US05559244A1

  公开（公告）日：1996-09-24

  A process for preparing 1-(het)aryl-3-hydroxypyrazoles of the formula I ##STR1## where R is an unsubst. or subst. aromatic or heteroaromatic radical, n is 0, 1 or 2 and R' is a group which is stable under the reaction conditions, from propiolic acid esters of the formula II R'--C.tbd.C--CO.sub.2 R.sup.1 II where R.sup.1 is an alkyl, cycloalkyl or aryl group, and (het)arylhydrazines of the formula III R--NH--NH.sub.2 III in a solvent in the presence of a base, which comprises first mixing II and III with one another in a solvent and then treating this mixture with the base at from 0.degree. C. to 60.degree. C. is described.

  本发明涉及一种制备式I的1-(het)aryl-3-羟基吡唑的过程：##STR1## 其中R是未取代或取代的芳香或杂环芳基，n为0,1或2，R'是在反应条件下稳定的基团，从式II的丙炔酸酯中制备，式II为R'--C.tbd.C--CO.sub.2 R.sup.1 II，其中R.sup.1是烷基，环烷基或芳基基团，以及式III的(het)芳基肼，式III为R--NH--NH.sub.2 III，在溶剂中存在碱的情况下。该方法包括首先将II和III混合在溶剂中，然后在0℃至60℃下用碱处理该混合物。